Trial Profile

A study to evaluate how well single and multiple doses of O3R-5671-PRO are tolerated in healthy adult subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs O3R 5671 (Primary)
Indications Inflammatory bowel diseases; Psoriasis
Focus Adverse reactions; First in man
Sponsors Onco3R Therapeutics

Most Recent Events

29 Sep 2025 New trial record
04 Sep 2025 According to Onco3R Therapeutics media release, the company announced the approval of a Clinical Trial Application (CTA) by the Belgian regulatory authorities for its SIK3 inhibitor O3R-5671. The trial will be conducted at the SGS Clinical Pharmacology Unit in Antwerp, a leading clinical research center in Belgium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com